Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib

Leukemia

Volumn 28, Issue 3, 2014, Pages 716-719

  Schaab, C ^a,b   Oppermann, F S ^a   Klammer, M ^a   Pfeifer, H ^c   Tebbe, A ^a   Oellerich, T ^c,d   Krauter, J ^e   Levis, M ^f   Perl, A E ^g   Daub, H ^a   Steffen, B ^c   Godl, K ^a   Serve, H ^c,d  

^a Evotec München GmbH Dept of Bioinformatics   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD135 ANTIGEN; ONCOPROTEIN; PROTEIN BCL 11A; PROTEOME; QUIZARTINIB; RAN BINDING PROTEIN 3; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BIOINFORMATICS; BONE MARROW; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; LEUKEMIA CELL; LEUKEMIA REMISSION; MASS SPECTROMETRY; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; BIOLOGICAL MARKERS; BONE MARROW CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PHENYLUREA COMPOUNDS; PHOSPHOPROTEINS; PROTEOME;

EID: 84895800838     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.347     Document Type: Letter

References (13)

1. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984-2992.
2. Cortes JE, Perl AE, Dombret H, Kayser S, Steffen B, Rousselot P et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of Quizartinib (AC220) in patientsZ60 years of age with FLT3 ITD positive or negative relapsed/refractory. AML Blood (ASH Ann Meeting Abstr) 2012; 120: Abstract 48.
3. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008; 26: 1367-1372.
4. Klammer M, Dybowksi JN, Hoffmann D, Schaab C. Identification of significant features by a global mean rank test. BMC Bioinfo 2013 (Submitted
5. Saiki Y, Yamazaki Y, Yoshida M, Katoh O, Nakamura T. Human EVI9, a homologue of the mouse myeloid leukemia gene, is expressed in the hematopoietic progenitors and downregulated during myeloid differentiation of HL60 cells. Genomics 2000; 70: 387-391.
6. Yin B, Delwel R, Valk PJ, Wallace MR, Loh ML, Shannon KM et al. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood 2009; 113: 1075-1085.
7. Dai F, Lin X, Chang C, Feng XH. Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of TGF-beta signaling. Dev Cell 2009; 16: 345-357.
8. Yoon SO, Shin S, Liu Y, Ballif BA, Woo MS, Gygi SP et al. Ran-binding protein 3 phosphorylation links the Ras and PI3-kinase pathways to nucleocytoplasmic transport. Mol Cell 2008; 29: 362-375.
9. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Bohmer FD et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 2009; 36: 326-339.
10. Klammer M, Kaminski M, Zedler A, Oppermann F, Blencke S, Marx S et al. Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell proteomics 2012; 11: 651-668.
11. Gakovic M, Shu X, Kasioulis I, Carpanini S, Moraga I, Wright AF. The role of RPGR in cilia formation and actin stability. Hum mol genet 2011; 20: 4840-4850.
12. Meier R, Muller PR, Hirt A, Leibundgut K, Ridolfi-Luthy A, Wagner HP. Differential phosphorylation of lamin B2 in normal and leukemic cells. Leuk Res 1997; 21: 841-847.
13. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1229-1239..